Overview
What is Multidisciplinary Association For Psychedelic Studies Inc?
The Multidisciplinary Association for Psychedelic Studies Inc, headquartered in San Jose, California, is a nonprofit organization dedicated to advancing medical research and education through the careful use of psychedelics. In 2022, MAPS spearheaded clinical trials investigating MDMA-assisted therapy for PTSD and supported regulatory activities in preparation for a new drug application submission to the FDA. These efforts included the second phase 3 trial that continued until April 2022, and the MAPS Public Benefit Corporation's enrollment in MT1 study comparing the effects of MDMA-assisted therapy and placebo. To ensure access to this investigational therapy if it is approved, MAPS began discussions with the American Medical Association and the Veterans Administration. They also provided public education through presentations, publications, and media interviews, reaching millions of people in 2022. The Zendo Project's psychedelic harm reduction program provided in-person services at events like Burning Man and trained volunteers to offer peer support services to over 600 individuals. MAPS, with 58 employees, is a research and educational organization committed to clinical research, honest public education, harm reduction, and advocacy.
Official website here: www.maps.org
Is Multidisciplinary Association For Psychedelic Studies Inc legitimate?
Multidisciplinary Association For Psychedelic Studies Inc is a legitimate nonprofit organization registered as a 501(c)(3) entity. Multidisciplinary Association For Psychedelic Studies Inc submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Here are some key statistics you may want to consider:
Executive Compensation: $1,241,405
Professional Fundraising Fees: $0
Other Salaries and Wages: $3,468,063
For more financial information, click here
Official website here: www.maps.org
What is the mission statement of Multidisciplinary Association For Psychedelic Studies Inc?
The Multidisciplinary Association for Psychedelic Studies (MAPS) is a non-profit organization dedicated to advancing medical research and education surrounding the therapeutic uses of psychedelics and marijuana. MAPS pursues this mission through various means, including clinical trials, therapist training, public education, harm reduction, and advocacy. In 2022, MAPS sponsored clinical trials investigating MDMA-assisted therapy for PTSD and supported regulatory activities for the proposed New Drug Application (NDA) submission to the US Food and Drug Administration (FDA). Additionally, MAPS prepared clinical study reports for 17 of its sponsored clinical trials of MDMA-assisted therapy for PTSD in adults and healthy volunteers. To expand access to investigational therapy if it's approved, MAPS initiated discussions with the American Medical Association and the Veterans Administration. MAPS also engaged in public education by presenting at conferences, publishing bulletins, articles, and books, and providing interviews to various media outlets. MAPS' Zendo Project's psychedelic harm reduction program offered in-person services at events like Burning Man and trained volunteers to provide peer support to individuals experiencing challenging psychological experiences.
Official website here: www.maps.org
Who is the CEO of Multidisciplinary Association For Psychedelic Studies Inc?
Richard Doblin is the President & Executive Director of Multidisciplinary Association For Psychedelic Studies Inc.
Official website here: www.maps.org
What is the revenue of Multidisciplinary Association For Psychedelic Studies Inc?
Multidisciplinary Association For Psychedelic Studies Inc's revenue in 2022 was $16,331,336.
Official website here: www.maps.org
Who are the executives of Multidisciplinary Association For Psychedelic Studies Inc and what are their salaries?
The average compensation at Multidisciplinary Association For Psychedelic Studies Inc during 2022 was $81,198. There are 58 employees and 140 volunteers at Multidisciplinary Association For Psychedelic Studies Inc.
Here are 19 key members and their salaries:
- Amy Emerson (Director)
- Andrew Mo Septimus (Chief Financial Officer)
- Raymond Allen (General Counsel)
- Federico Menapace (Chief Strategy Officer)
- Kris Lotlikar (Deputy Director)
- Richard Rick Doblin (President & Executive Director)
- Betty Aldworth (Director Of Communications & Marketing)
- Sue Melnyk (Director Of Development)
- Alia Lillenstein (Director Of Medical Affairs)
- Kynthia Brunette (Crm System Specialist)
- Lianne Gillooly (Strategic Initiatives Officer)
- Ismail Ali (Director Of Policy And Advocacy)
- Steven Huang (Jedi Officer)
- David Bronner (Director)
- Vicky Dulai (Treasurer & Director)
- John Gilmore (Secretary & Director)
- Victoria Hale (Director, Chair)
- Carl Hart (Director)
- Joe Green (Director)
Official website here: www.maps.org
Where can I find the form 990 for Multidisciplinary Association For Psychedelic Studies Inc?
The Multidisciplinary Association For Psychedelic Studies Inc’s most recent form 990 was submitted in 2022 and can be accessed here
Official website here: www.maps.org
Learn more at the official website: www.maps.org
Mission Statement of Multidisciplinary Association For Psychedelic Studies Inc
The Multidisciplinary Association for Psychedelic Studies Inc (MAPS) is a research and educational organization dedicated to developing medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. MAPS' mission is to facilitate the exploration of these substances' therapeutic potential through clinical research, therapist training, public education, harm reduction, and advocacy.
MAPS has been at the forefront of psychedelic research, sponsoring clinical trials studying investigational MDMA-assisted therapy for PTSD. In 2022, the organization completed enrollment for a study comparing the effects of MDMA-assisted therapy and therapy with placebo on mood and psychological experience in people trained to practice investigational MDMA-assisted therapy. MAPS also initiated the preparation of clinical study reports for 17 MAPS-sponsored clinical trials of investigational MDMA-assisted therapy for the treatment of PTSD in adults and healthy volunteers. These efforts aim to pave the way for potential reimbursement for psychedelic-assisted therapies by discussing code development with the American Medical Association.
In addition to research, MAPS is committed to providing education through presentations at public conferences and webinars, publishing articles on websites and social media channels, and publishing books in the trade. In 2022, MAPS educated millions through media exposures in online, broadcast, and print publications, including NPR, CNN, NBC, CBS, ABC, TIME, and Newsweek. The organization's Zendo Project's psychedelic harm reduction program provided in-person services at Burning Man, training volunteers to offer peer support services to over 600 individuals having challenging psychological experiences. As MAPS continues to push for the acceptance and legalization of psychedelic therapies, it remains an influential force in shaping the future of this field.
Impact
This information is meant to be a general summary of Multidisciplinary Association For Psychedelic Studies Inc. Please take the time to review official sources before making any decisions based upon the content provided here.
Thursday, August 15, 2024
MAPS has had a significant impact on the field of medical research and education by sponsoring clinical trials studying investigational MDMA-assisted therapy for PTSD. They have been actively involved in funding regulatory activities supporting the proposed new drug application submission to the U.S. Food and Drug Administration. Through their efforts, MAPS has enrolled participants in Phase 3 trials, collaborated with the FDA to develop study protocols, and collected valuable data for analysis.
Additionally, MAPS has played a crucial role in providing public education through various platforms, including presentations at conferences, webinars, publications, and interviews with leading media outlets. By reaching millions of individuals, MAPS has helped raise awareness and understanding of psychedelic-assisted therapies.
Furthermore, the organization's Zendo Project has contributed to harm reduction by providing in-person services at events like Burning Man and training volunteers to offer peer support to individuals experiencing challenging psychological experiences. This initiative demonstrates MAPS' commitment to ensuring the safe and responsible use of psychedelics.
Overall, MAPS' dedication to medical research, education, harm reduction, and advocacy has made a significant impact on promoting the careful and beneficial use of psychedelics and marijuana in various contexts.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Assets and Liabilities:
Programs
Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.
EVENT AND CONFERENCE INCOME
Revenue
$146,284
ADMIN FEES
Revenue
$68,940
Organization Details
Founding Year
1986
Phone
(831) 429-6362
Principal Officer
Richard Doblin
Main Address
3141 STEVENS CREEK BLVD 40563, SAN JOSE, CA, 95117
Website
www.maps.org
NTEE Category
Code: H99Z - Medical research
If you are a representative of Multidisciplinary Association For Psychedelic Studies Inc and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.